Arvee Laboratories (India) Ltd. (IN:ARVEE)
:ARVEE
Want to see IN:ARVEE full AI Analyst Report?
Top Page
Arvee Laboratories (India) Ltd.
(ARVEE)
Select Model
Select Model
Rating:51Neutral
Price Target:
₹158.00
▼(-34.80% Downside)
Action:Reiterated
Date:05/23/26
The score is held back primarily by weak recent cash flow (negative operating and free cash flow) and a high P/E valuation. These are partially offset by a notably strong, low-leverage balance sheet and neutral technical momentum.
Positive Factors
Balance sheet strength
Very low leverage and steadily growing equity provide durable financial flexibility. This lowers refinancing risk, supports counter-cyclical spending, and preserves capacity for capex or M&A when demand recovers, making the business more resilient over a multi-quarter horizon.
Negative Factors
Negative recent cash flow
Recent negative operating and free cash flow indicate current earnings are not translating into liquidity, likely from working-capital swings or elevated spend. Prolonged cash absorption can force external financing or curtail investments, weakening durable financial flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Very low leverage and steadily growing equity provide durable financial flexibility. This lowers refinancing risk, supports counter-cyclical spending, and preserves capacity for capex or M&A when demand recovers, making the business more resilient over a multi-quarter horizon.
Read all positive factors
Arvee Laboratories (India) Ltd. (ARVEE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.82B
Dividend YieldN/A
Average Volume (3M)1.40K
Price to Earnings (P/E)72.2
Beta (1Y)1.29
Revenue Growth-18.12%
EPS Growth17.54%
CountryIN
Employees65
SectorHealthcare
Sector Strength45
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)1.24
Shares Outstanding11,020,000
10 Day Avg. Volume2,098
30 Day Avg. Volume1,398
Financial Highlights & Ratios
PEG Ratio3.35
Price to Book (P/B)4.37
Price to Sales (P/S)4.69
P/FCF Ratio-50.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Arvee Laboratories (India) Ltd. Business Overview & Revenue Model
Company Description
Arvee Laboratories (India) Ltd., established in 2012 and headquartered in Ahmedabad, India, specializes in the production and distribution of various specialized chemicals throughout the country. The company's product line includes a range of poly...
How the Company Makes Money
null...
Arvee Laboratories (India) Ltd. Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
82
Very Positive
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 353.65M | 315.14M | 384.87M | 303.42M | 612.76M | 403.27M |
| Gross Profit | 159.88M | 111.68M | 121.63M | 41.49M | 173.09M | 138.08M |
| EBITDA | 31.37M | 31.98M | 42.69M | 35.78M | 86.34M | 61.90M |
| Net Income | 13.74M | 25.26M | 21.47M | 10.52M | 41.19M | 25.74M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 432.57M | 381.58M | 381.99M | 386.85M | 386.85M |
| Cash, Cash Equivalents and Short-Term Investments | 59.75M | 32.82M | 49.06M | 18.65M | 8.92M | 31.08M |
| Total Debt | 0.00 | 11.13M | 10.33M | 10.00M | 10.00M | 31.31M |
| Total Liabilities | -312.61M | 95.30M | 68.97M | 90.85M | 106.23M | 147.43M |
| Stockholders Equity | 312.61M | 337.88M | 312.61M | 291.14M | 280.62M | 239.42M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -29.02M | -17.35M | 10.78M | 14.45M | 16.52M |
| Operating Cash Flow | 0.00 | -694.00K | 1.19M | 36.64M | 29.29M | 40.16M |
| Investing Cash Flow | 0.00 | 2.17M | -17.91M | -21.63M | -12.58M | 592.61K |
| Financing Cash Flow | 0.00 | 802.00K | 333.00K | -1.88M | -24.17M | -60.51M |
Arvee Laboratories (India) Ltd. Technical Analysis
Neutral
242.32
Price Trends
164.06
Positive
158.92
Positive
168.20
Negative
Market Momentum
1.73
Negative
50.69
Neutral
33.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ARVEE, the sentiment is Neutral. The current price of 242.32 is above the 20-day moving average (MA) of 163.31, above the 50-day MA of 164.06, and above the 200-day MA of 168.20, indicating a neutral trend. The MACD of 1.73 indicates Negative momentum. The RSI at 50.69 is Neutral, neither overbought nor oversold. The STOCH value of 33.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:ARVEE.
Arvee Laboratories (India) Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ₹1.82B | 72.21 | ― | ― | -18.12% | 17.54% | |
51 Neutral | ₹575.12M | 20.74 | ― | ― | -14.99% | 399.30% | |
49 Neutral | ₹387.78M | -1.15 | ― | ― | -82.35% | -130.97% | |
45 Neutral | ₹1.31B | 93.06 | ― | ― | ― | ― | |
39 Underperform | ₹504.95M | -1.42 | ― | ― | -35.33% | -65.64% |
* Healthcare Sector Average
IN:ARVEE
Arvee Laboratories (India) Ltd.
164.83
3.85
2.39%
IN:BALAXI
Balaxi Pharmaceuticals Limited
23.67
-26.60
-52.91%
IN:BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
35.34
-11.16
-24.00%
IN:LASA
Lasa Supergenerics Ltd.
7.74
-2.18
-21.98%
IN:VIVIMEDLAB
Vivimed Labs Limited
6.09
1.19
24.29%
Arvee Laboratories (India) Ltd. Corporate Events
Exchange Seeks Clarification From Arvee Laboratories After Sharp Share Price Move
Apr 13, 2026
The stock of Arvee Laboratories (India) Ltd. has shown significant price movement, prompting the exchange to step in and seek clarification from the company. The bourse aims to ensure investors have the latest relevant information and to safeguard...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.